Moreover, non-responding patients showed also elevated serum levels of inflammatory molecules S100A8/A9 and high mobility group box 1 (HMGB1), suggesting that MDSC and chronic inflammatory factors can be not only therapeutic targets in cancer patients but also serve as new biomarkers detecting the group of advanced melanoma patients who may benefit from Ipilimumab therapy [135]. The gene discussed is HMGB1; the disease is cancer.